PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 201 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2015. The put-call ratio across all filers is 0.90 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $360,000 | -20.4% | 6,090 | -8.4% | 0.00% | -33.3% |
Q1 2018 | $452,000 | -54.8% | 6,646 | -34.4% | 0.00% | -57.1% |
Q4 2017 | $1,001,000 | +241.6% | 10,129 | +314.1% | 0.01% | +250.0% |
Q3 2017 | $293,000 | +38.9% | 2,446 | +1.3% | 0.00% | +100.0% |
Q2 2017 | $211,000 | +3.9% | 2,414 | -20.4% | 0.00% | 0.0% |
Q3 2016 | $203,000 | +76.5% | 3,031 | -21.2% | 0.00% | 0.0% |
Q2 2016 | $115,000 | +16.2% | 3,848 | +13.7% | 0.00% | 0.0% |
Q1 2016 | $99,000 | -49.7% | 3,383 | +34.4% | 0.00% | 0.0% |
Q4 2015 | $197,000 | +68.4% | 2,518 | +62.5% | 0.00% | 0.0% |
Q3 2015 | $117,000 | -10.7% | 1,550 | +37.7% | 0.00% | 0.0% |
Q2 2015 | $131,000 | -32.5% | 1,126 | +37.0% | 0.00% | -50.0% |
Q1 2015 | $194,000 | +25.2% | 822 | +0.1% | 0.00% | +100.0% |
Q4 2014 | $155,000 | -29.2% | 821 | -10.7% | 0.00% | -50.0% |
Q3 2014 | $219,000 | +236.9% | 919 | -6.4% | 0.00% | +100.0% |
Q2 2014 | $65,000 | – | 982 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
TOBAM | 318,384 | $23,994,000 | 0.94% |
Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |